布地奈德用于熊去氧胆酸应答不足的原发性胆汁性胆管炎的安慰剂对照随机试验
这项安慰剂对照双盲随机试验纳入62例经熊去氧胆酸治疗至少6个月、碱性磷酸酶>1.5倍正常上限且组织学证实有肝脏炎症活动的原发性胆汁性胆管炎患者,按2:1随机接受布地奈德9 mg/日或安慰剂治疗36个月。因招募困难研究对主要疗效分析把握度不足,配对活检亚组(n=43)的组织学主要终点未达到;但布地奈德组在12、24、36个月时碱性磷酸酶<1.67倍正常上限、碱性磷酸酶下降≥15%且胆红素正常的患者比例高于安慰剂组,布地奈德组35%患者碱性磷酸酶恢复正常而安慰剂组为9%(p=0.023)。
要点
- 布地奈德联合熊去氧胆酸未改善原发性胆汁性胆管炎患者的肝脏组织学。
- 布地奈德组35%患者碱性磷酸酶恢复正常,安慰剂组为9%(p=0.023)。
- 布地奈德组严重不良事件10例,安慰剂组7例。
核心结论
- 布地奈德附加治疗与熊去氧胆酸应答不足的原发性胆汁性胆管炎患者肝脏组织学改善无关,但次要分析显示疾病活动度生化标志物有改善。
研究设计与样本
- 安慰剂对照双盲随机试验,纳入62例经熊去氧胆酸治疗至少6个月、Ishak评分组织学证实肝脏炎症活动且碱性磷酸酶>1.5倍正常上限的原发性胆汁性胆管炎患者。
- 参与者按2:1随机接受布地奈德9 mg/日或安慰剂每日一次治疗36个月,同时维持熊去氧胆酸12-16 mg/kg体重/日治疗。
- 主要疗效定义为肝脏组织学炎症改善且纤维化无进展,次要结局包括肝损伤生化标志物变化。
主要发现
- 因招募困难,研究对主要疗效分析把握度不足;仅比较有配对活检的患者(n=43)时,主要组织学终点未达到(p>0.05)。
- 12、24、36个月时,布地奈德组碱性磷酸酶<1.67倍正常上限、碱性磷酸酶下降≥15%且胆红素正常的患者比例均高于安慰剂组(各时间点p<0.05)。
- 与安慰剂相比,布地奈德降低平均碱性磷酸酶,布地奈德组35%患者碱性磷酸酶恢复正常,安慰剂组为9%(p=0.023)。
- 布地奈德组10例患者发生严重不良事件,安慰剂组7例。
关键数值与推荐
- 主要组织学终点未达到(p>0.05,配对活检n=43)。
- 布地奈德组35%患者碱性磷酸酶恢复正常 vs 安慰剂组9%(p=0.023)。
- 12、24、36个月时碱性磷酸酶<1.67倍正常上限、碱性磷酸酶下降≥15%且胆红素正常的患者比例布地奈德组高于安慰剂组(各时间点p<0.05)。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 招募困难导致研究对主要疗效分析把握度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In patients with primary biliary cholangitis (PBC), the efficacy of budesonide, a synthetic corticosteroid displaying high first-pass metabolism, is unresolved. In a placebo-controlled, double-blind trial, we evaluated the added-value of budesonide in those with PBC and ongoing risk of progressive disease despite ursodeoxycholic acid (UDCA) treatment. METHODS: We evaluated 62 patients with PBC who had histologically confirmed hepatic inflammatory activity, according to the Ishak score, and an alkaline phosphatase (ALP) >1.5× upper limit of normal (ULN), after at least 6 months of UDCA therapy. Participants were randomly assigned 2:1 to receive budesonide (9 mg/day) or placebo once daily, for 36 months, with UDCA treatment (12-16 mg/kg body weight/day) maintained. Primary efficacy was defined as improvement of liver histology with respect to inflammation and no progression of fibrosis. Secondary outcomes included changes in biochemical markers of liver injury. RESULTS: Recruitment challenges resulted in a study that was underpowered for the primary efficacy analysis. Comparing patients with paired biopsies only (n = 43), the primary histologic endpoint was not met (p >0.05). The proportion of patients with ALP <1.67×ULN, a ≥15% decrease in ALP and normal bilirubin was higher in the budesonide group than in the placebo group at 12, 24, and 36 months (p <0.05, each). In contrast to placebo, budesonide reduced mean ALP and 35% of budesonide-treated patients achieved normalisation of ALP (placebo 9%; p = 0.023). Serious adverse events occurred in 10 patients receiving budesonide and 7 patients receiving placebo. CONCLUSION: Budesonide add-on therapy was not associated with improved liver histology in patients with PBC and insufficient response to UDCA; however, improvements in biochemical markers of disease activity were demonstrated in secondary analyses. LAY SUMMARY: Around one-third of patients with primary biliary cholangitis (PBC) needs additional medical therapy alongside ursodeoxycholic acid (UDCA) treatment. In this clinical trial, the addition of the corticosteroid budesonide did not improve liver histology; there were however relevant improvements in liver blood tests. CLINICALTRIALS. GOV NUMBER: NCT00746486.
引用
- Hirschfield GM, Beuers U, Kupcinskas L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2020. PMID: 32950590. doi:10.1016/j.jhep.2020.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。